#United States #Novo Nordisk #Halia Therapeutics #Lehi #HT-6184

Halia Therapeutics Secures Novo Nordisk Golden Ticket

In a remarkable achievement, Halia Therapeutics, based in Lehi, Utah, proudly announces its recent award of the Novo Nordisk Golden Ticket. This prestigious recognition is aimed at innovative biotech firms specializing in transformative therapies targeting obesity and cardiometabolic diseases. The Golden Ticket, provided by Novo Nordisk, includes crucial resources such as a dedicated lab bench, desk space, and a year-long membership to BioLabs. Notably, this allows Halia to pursue private lab space possibilities based on availability, as well as immediate access to BioLabs facilities in Heidelberg or Paris, enhancing their research capabilities.

The award offers more than just a workspace; it is a gateway to Novo Nordisk's dedicated scientific and business experts, providing bespoke mentorship and networking opportunities. David J. Bearss, Ph.D., CEO of Halia Therapeutics, expressed the significance of this recognition, stating, "This award validates our approach to addressing chronic inflammation and diseases related to obesity. The resources afforded by this partnership position us favorably to propel HT-6184 into clinical development."

Halia Therapeutics is pioneering the development of HT-6184, an innovative NEK7/NLRP3 inflammasome inhibitor meticulously designed to combat metaflammation — a chronic, low-grade inflammation intricately linked with obesity, metabolic dysfunction, and associated disorders. Preclinical studies have indicated that HT-6184 might enhance the effectiveness of GLP-1 receptor agonists, aiding weight loss while mitigating inflammation and preserving lean muscle mass. The company anticipates the commencement of a Phase 2 clinical trial combining HT-6184 with Semaglutide early in 2025.

This achievement not only fortifies Halia's standing within the European biotech community but also lays a vital foundation for global outreach and alliances. As the biotech realm continues to evolve rapidly, Halia's access to premier resources and industry expertise presents a significant advantage.

About Halia Therapeutics

Established in Lehi, Utah, Halia Therapeutics is a clinical-stage biopharmaceutical enterprise focusing on novel therapies for chronic inflammatory disorders and neurodegenerative diseases. The company's flagship candidate, HT-6184, targets the NEK7/NLRP3 inflammasome pathway, intending to regulate inflammation stemming from obesity and metabolic ailments. Furthermore, Halia is investigating HT-4253, a LRRK2 inhibitor, focused on its implications for diseases linked to neuroinflammation. With a commitment to tackling the fundamental drivers of inflammation-driven health challenges, Halia aims to address conditions with significant unmet medical needs, including obesity and neurodegenerative diseases such as Alzheimer's. For more details, you can visit Halia’s official website and connect with the company on LinkedIn and Twitter (X).